Eli Lilly's obesity drug, tirzepatide (Zepbound), significantly reduced sleep apnea severity in overweight and obese patients.

Eli Lilly's obesity drug, tirzepatide (Zepbound), significantly reduced obstructive sleep apnea in overweight and obese patients, according to two late-stage clinical trials. The drug led to a mean reduction of up to 63% in the apnea-hypopnea index (AHI), which measures the severity of sleep apnea. The results suggest Zepbound could be an effective treatment option for millions of Americans diagnosed with moderate to severe sleep apnea.